Structure Therapeutics (GPCR) Gained from Favorable Clinical Data

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap Growth Fund”. A copy of the letter can be downloaded here. U.S. equity markets navigated a quarter supported by optimism about potential monetary easing and caution regarding economic growth and valuations. Early gains were driven by strong AI-related earnings and the US Federal Reserve’s rate cut in October, which improved expectations for financial conditions. However, market sentiment cooled later in the quarter. Despite this moderation, the quarter contributed positively to robust annual results. Small caps delivered an annual return of 12.8% with a 2.2% Q4 gain. Value outperformed growth as per the Russell family of indices. In Q4 2025, The Meridian Small Cap Growth Fund returned 0.90% (net) compared to the Russell 2000 Growth Index’s 1.22% return. In addition, please check the Fund’s top five holdings to know its best picks in 2025.

In its fourth-quarter 2025 investor letter, Meridian Small Cap Growth Fund highlighted stocks like Structure Therapeutics Inc. (NASDAQ:GPCR). Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage global biopharmaceutical company that focuses on developing oral small-molecule therapeutics to treat various chronic diseases. On February 18, 2026, Structure Therapeutics Inc. (NASDAQ:GPCR) stock closed at $68.36 per share. One-month return of Structure Therapeutics Inc. (NASDAQ:GPCR) was -25.59%, and its shares are up 192.26% over the past twelve months. Structure Therapeutics Inc. (NASDAQ:GPCR) has a market capitalization of $4.829 billion.

Meridian Small Cap Growth Fund stated the following regarding Structure Therapeutics Inc. (NASDAQ:GPCR) in its fourth quarter 2025 investor letter:

"Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical firm focused on developing oral therapies targeting obesity and metabolic diseases. The company’s lead oral candidate has shown promising efficacy and a lower-than-anticipated discontinuation rate in Phase II trials, positioning it as a viable alternative to injectable GLP-1 medications. Following the release of favorable clinical data, the stock advanced, bolstered by a successful capital raise that is expected to adequately support funding through Phase III trials. The therapy’s oral administration format, combined with its leading safety profile, enhances the company’s attractiveness as a potential acquisition target within the GLP-1 competitive landscape."

Structure Therapeutics Inc. (NASDAQ:GPCR) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 42 hedge fund portfolios held Structure Therapeutics Inc. (NASDAQ:GPCR) at the end of the third quarter, compared to 44 in the previous quarter. While we acknowledge the potential of Structure Therapeutics Inc. (NASDAQ:GPCR) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Structure Therapeutics Inc. (NASDAQ:GPCR) and shared a list of best booming stocks to buy. In addition, please check out our hedge fund investor letters Q4 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.